FDA approves Roche ’s Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer

Roche today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).

https://www.roche.com/investors/updates/inv-update-2019-03-19.htm

Source: Roche Investor Update - March 19, 2019 Category: Pharmaceuticals Source Type: news